Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16"

Transcription

1 Type 2 Diabetes Tabinda Dugal GP Day 4/05/16

2

3 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget

4 Projections.. 5 million by 2025 Youngest patient?

5

6 T2DM Type 2 diabetes is a chronic metabolic condition characterised by insulin resistance (that is, the body's inability to effectively use insulin) insufficient pancreatic insulin production, resulting in high blood glucose levels (hyperglycaemia)

7 T2DM Type 2 diabetes is commonly associated with obesity, Physical inactivity, Raised blood pressure, Disturbed blood lipid levels A tendency to develop thrombosis, and therefore is recognised to have an increased cardiovascular risk

8 T2DM It is associated with long-term microvascular and macrovascular complications, together with reduced quality of life and life expectancy.

9

10 NICE 2015 Monitor blood pressure every 1 2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140/80 mmhg (below 130/80 mmhg if there is kidney, eye or cerebrovascular damage)

11 NICE 2015 Involve adults with type 2 diabetes in decisions about their individual HbA1c target. Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. [new 2015] In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5%) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol/mol (7.0%) and intensify drug treatment. [new 2015] Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery orthe person is pregnant, or is planning to become pregnant.

12

13

14

15

16

17

18

19

20

21 % of Subjects n = 404 We Are NOT At Goal % 7% GOAL Survey 12.4% 7.8% 17.0% 25.8% 37.0% 37.2% >8% A1C >10% >9% >8% 7-8% <7% Only 7% of adults with diabetes in NHANES attained: A1C level <7% Blood pressure <130/80 mm Hg Total cholesterol <200 mg/dl Adults aged years with previously diagnosed diabetes who participated in the interview and examination components of the National Health Examination Survey (NHANES), Saydah SH et al. JAMA. 2004;291:

22 Many patients are still failing to meet their treatment targets UNCONTROLLED 35% of people nationally OVERWEIGHT 90% of adults with type 2 diabetes are not meeting their treatment target of an HbA 1c of 58 mmol/mol (7.5%) 1 with type 2 diabetes are overweight or obese 2 How does this compare to your local figures? 1. Diabetes UK (2015) State of the Nation: Challenges for 2015 and Beyond (England). Available at: State-of-the-nation-challenges-for-2015-and-beyond/ (accessed ) 2. Public Health England (2014) Adult obesity and type 2 diabetes. Available at: (accessed )

23 Renal Handling of Glucose (180 L/day) (900 mg/l)=162 g/day Glucose SGLT2 S1 90% S3 SGLT1 10% No Glucose

24

25

26 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators

27 EMPA-REG CONCLUSIONS Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT )

28 Number of patients <6 <6 Number of patients Type 2 HbA 1c levels when initiating insulin therapy Average HbA 1c is 10.1% Average HbA 1c is 10.4% Basal Only Basal Bolus Patients with HbA 1c recorded:19533 Patients with HbA 1c recorded: ,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1, ,400 1,200 1, Level of HbA 1c control Level of HbA 1c control Source: CSD Patient Data, MAT to May 2013

29 < <6 12+ Number of patients Number of patients Type 2 HbA 1c control levels in UK patients on insulin Average HbA 1c is 8.8% Average HbA 1c is 8.8% Basal Only 39% of patients have HbA 1c >9%: 44,166 Basal Bolus 39% of patients have HbA 1c >9%: 95,676 25,000 20,000 15,000 10,000 40,000 33,000 30,000 25,000 20,000 15,000 5,000 10,000 5, Level of HbA 1c control Level of HbA 1c control Source: CSD Patient Data, MAT to May 2013

30 Effects of Meals and Snacks Dietary fiber Targets of grams/day Can be difficult to achieve Improves postprandial numbers for some Soluble fiber can lower cholesterol numbers Increases satiety Alcohol Can cause hypoglycemia, especially when taken without carbohydrates Don t forget, it s a source of calories Moderate intake associated with improved heart health

31 Effects of Physical Activity on Glucose Immediate effects Metabolism During and several hours after exercise Delayed effects 4 12 hours after exercise Long-lasting effects Improves insulin sensitivity Implications for glucose monitoring

32 Hypoglycemia Treatment Options Frequent Decrease medication Usually sulfonylurea or insulin Special problems associated with SU Intermittent Due to too little food Adjust food Decrease insulin dose if on insulin Due to too much physical activity Add carbs for extra fuel Decrease insulin dose if on insulin

33 Hyperglycemia Treatment Options Reduce food portions and/or carbohydrates Add in aerobic physical activity Resistance exercise adds benefit also Increase medication effect Dosage, timing Add new medication

34 Listening to Your Patient Collect the information Thank them for bringing it in Ask what they think about their numbers Look for barriers to checking glucoses Ask if you could share some of your thoughts on their numbers Give a brief interpretation Using AHH, emphasize average glucose goal and A1C Decide, with the patient, about an approach to take Changing food, activity, medication Discuss follow-up

35 The Basics Just Say AHH A1C and average blood glucose On target? (Do they know their target?) Hypoglycemia (<4 mmol/dl) Fasting or postprandial? Frequent or intermittent? Symptoms? Hyperglycemia (>fasting/postprandial target) Fasting or postprandial? Frequent or intermittent?

36 Weight loss 13% wt loss 0.6gm from pancreas Reversal of diabetes

37 New Diagnosis and control "Prompted by the case of a newly diagnosed diabetic lady who experienced a deterioration of vision after rapid lowering of her blood sugar, in Cornwall we have reviewed the advice regarding management of diabetes in newly diagnosed type 2 diabetic people having significant hyperglycaemia and whose retinopathy status is unknown.

38 Case Through regular GP/Diabetes updates we have disseminated advice to our colleagues in primary care that newly diagnosed type 2 diabetics should be offered diabetic retinopathy screening as soon as possible, and importantly, not to initiate rapid improvement in glycaemic control until the retinopathy status is known to be mild (R1) Our screening service operates from some 70 sites throughout Cornwall and, in practice, we can usually offer a screening appointment within one week for such patients. Patients with sight threatening retinopathy (R2 or R3) are fast-tracked for further assessment and treatment in the hospital eye service and with careful liaison with Primary Care Practitioners and where appropriate our diabetologists regarding glycaemic management.

39 Case In general, our diabetologists recommend lowering of blood sugar 0.5% or 6 mmol/mol every six months and a combination of insulin and metformin is frequently advised to achieve predicted control. It should also be recognised that some medications, e.g. sulphonylureas and/or SGLT2 blockers should be avoided as they have the potential to lead to a poweful, sudden reduction of blood sugar with adverse effects on preexisting retinopathy."

40 Keep Cycling

41

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB

Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees

More information

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de

More information

Initiate Atorvastatin 20mg daily

Initiate Atorvastatin 20mg daily Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to

More information

Causes, incidence, and risk factors

Causes, incidence, and risk factors Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,

More information

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used

More information

Understanding diabetes Do the recent trials help?

Understanding diabetes Do the recent trials help? Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.

More information

Algorithms for Glycemic Management of Type 2 Diabetes

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach

Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

Section 5: Type 2 Diabetes

Section 5: Type 2 Diabetes SECTION OVERVIEW Definition and Symptoms Blood Glucose Monitoring Healthy Eating Physical Activity Oral Medication Insulin Sharps Disposal Definition and Symptoms Type 2 diabetes is occurring more frequently

More information

Type 2 Diabetes. Management and Medication. HELPLINE: 01604 622837 www.iddtinternational.org

Type 2 Diabetes. Management and Medication. HELPLINE: 01604 622837 www.iddtinternational.org I N D E P E N D E N T D I A B E T E S T R U S T Type 2 Diabetes Management and Medication A charity supporting and listening to people who live with diabetes HELPLINE: 01604 622837 www.iddtinternational.org

More information

Type 2 Diabetes workshop notes

Type 2 Diabetes workshop notes Group 1 notes Abi / Nicole Type 2 Diabetes workshop notes 4.1 Population The group discussed the following sub groups that may need addressing: Men-as they tend to die earlier compared with women, their

More information

Diabetes in Primary Care course MCQ Answers 2016

Diabetes in Primary Care course MCQ Answers 2016 Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE

More information

2. What Should Advocates Know About Diabetes? O

2. What Should Advocates Know About Diabetes? O 2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate

More information

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused

More information

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic

More information

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing

More information

Insulin-Treated Diabetes. Guidelines for assessment of fitness to work as Cabin Crew

Insulin-Treated Diabetes. Guidelines for assessment of fitness to work as Cabin Crew Insulin-Treated Diabetes Guidelines for assessment of fitness to work as Cabin Crew General Considerations As with all medical guidelines it is important that each individual case is assessed on its own

More information

This information explains the advice about type 2 diabetes in adults that is set out in NICE guideline NG28.

This information explains the advice about type 2 diabetes in adults that is set out in NICE guideline NG28. Information for the public Published: 2 December 2015 nice.org.uk About this information NICE guidelines provide advice on the care and support that should be offered to people who use health and care

More information

Cancer treatment and diabetes

Cancer treatment and diabetes Cancer treatment and diabetes Dr Daniel Morganstein Consultant Endocrinologist, 1 2 Diabetes and cancer Cancer and its treatment also poses challenges to managing diabetes Surgery Altered appetite Cachexia

More information

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising

More information

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step

More information

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term

More information

Introduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.

Introduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes. Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried

More information

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat?

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? After eating, most food is turned into glucose, the body s main source of energy. 1 Normal Blood

More information

Hi. This is Janet Beer for the Child Nutrition Programs at the Oregon Department of Education.

Hi. This is Janet Beer for the Child Nutrition Programs at the Oregon Department of Education. Slide 1 General Information for Serving Students with Diabetes Child Nutrition Programs Oregon Department of Education Hi. This is Janet Beer for the Child Nutrition Programs at the Oregon Department of

More information

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:

More information

Self-Monitoring Of Blood Glucose (SMBG)

Self-Monitoring Of Blood Glucose (SMBG) Self-Monitoring Of Blood Glucose (SMBG) Aim(s) and objective(s) It is important is to ensure that people with Diabetes are given the opportunity to self monitor their blood glucose appropriately as an

More information

Objectives. What Is Diabetes? 1/26/2015. Carbs & Meds & Meters, Oh My!: Diabetes in Pregnancy

Objectives. What Is Diabetes? 1/26/2015. Carbs & Meds & Meters, Oh My!: Diabetes in Pregnancy Carbs & Meds & Meters, Oh My!: Diabetes in Pregnancy Jan Tisdale RD, MPH, CDE Nutritionist / Certified Diabetes Educator UAB School of Medicine OB/GYN Maternal-Fetal Medicine 02/2015 Objectives Review

More information

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008 Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood

More information

When and how to start insulin: strategies for success in type 2 diabetes

When and how to start insulin: strategies for success in type 2 diabetes 1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology

More information

Cochrane Quality and Productivity topics

Cochrane Quality and Productivity topics Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Insulin Pump Therapy for Type 1 Diabetes

Insulin Pump Therapy for Type 1 Diabetes Insulin Pump Therapy for Type 1 Diabetes Aim(s) and objective(s) This guideline has been developed to describe which patients with Type 1 Diabetes should be referred for assessment for insulin pump therapy

More information

Diabetes Fundamentals

Diabetes Fundamentals Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence

More information

Starting Insulin Sooner Than Later

Starting Insulin Sooner Than Later Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration

More information

Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)

Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) EMA/467911/2014 Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) This is a summary of the risk management plan (RMP) for Xultophy, which details the measures to be

More information

Baskets of Care Diabetes Subcommittee

Baskets of Care Diabetes Subcommittee Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level

More information

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness

More information

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation

More information

4. Does your PCT provide structured education programmes for people with type 2 diabetes?

4. Does your PCT provide structured education programmes for people with type 2 diabetes? PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle

More information

Part B: 3 3. DIABETES MELLITUS. 3.1.1 Effects of diabetes on driving. 3.1.2 Evidence of crash risk. 3.2.1 Hypoglycaemia

Part B: 3 3. DIABETES MELLITUS. 3.1.1 Effects of diabetes on driving. 3.1.2 Evidence of crash risk. 3.2.1 Hypoglycaemia 3. DIABETES MELLITUS Refer also to section 6 Neurological conditions, section 2 Cardiovascular conditions, section 8 Sleep disorders section 10 Vision eye disorders. 3.1 Relevance to the driving task 3.1.1

More information

Diabetes for CNAs. This course has been awarded two (2.0) contact hours. This course expires on January 31, 2017.

Diabetes for CNAs. This course has been awarded two (2.0) contact hours. This course expires on January 31, 2017. Diabetes for CNAs This course has been awarded two (2.0) contact hours. This course expires on January 31, 2017. Copyright 2005 by RN.com. All Rights Reserved. Reproduction and distribution of these materials

More information

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years

More information

Effects of macronutrients on insulin resistance and insulin requirements

Effects of macronutrients on insulin resistance and insulin requirements Effects of macronutrients on insulin resistance and insulin requirements Dr Duane Mellor RD Assistant Professor in Dietetics, The University of Nottingham, UK Outline of Discussion Issues of determining

More information

Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.

Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention. Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention. Professor Paolo Pozzilli University Campus Bio-Medico, Rome Institute of Cell & Molecular Science, Queen Mary, University of

More information

Initiating & titrating insulin & switching in General Practice Workshop 1

Initiating & titrating insulin & switching in General Practice Workshop 1 Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes

More information

Insulin myths and facts

Insulin myths and facts london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest

More information

Glycaemic Control in Adults with Type 1 Diabetes

Glycaemic Control in Adults with Type 1 Diabetes Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

What is DIABETES? Gwen Hall Diabetes Specialist Nurse, Community Diabetes Services Portsmouth, Primary Care Team.

What is DIABETES? Gwen Hall Diabetes Specialist Nurse, Community Diabetes Services Portsmouth, Primary Care Team. What is DIABETES? By: Gwen Hall Diabetes Specialist Nurse, Community Diabetes Services Portsmouth, Primary Care Team. WHAT IS DIABETES? What is diabetes? In simple terms diabetes prevents your body converting

More information

An Overview and Guide to Healthy Living with Type 2 Diabetes

An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS This brochure was designed to help you understand the health goals to live a healthy lifestyle with type

More information

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria DIABETES MELLITUS By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria What is Diabetes Diabetes Mellitus (commonly referred to as diabetes ) is a chronic medical

More information

Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner

Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers

More information

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date

More information

School Nurse Role in Care and Management of the Child with Diabetes in Colorado Schools and Child Care Settings Position Statement 1 POSITION It is

School Nurse Role in Care and Management of the Child with Diabetes in Colorado Schools and Child Care Settings Position Statement 1 POSITION It is Schools and Child Care Settings Position Statement 1 POSITION It is the position of the Colorado Diabetes Resource Nurses that the school nurse is the only school staff member who has the skills, knowledge

More information

DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa

DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa DIABETES A chronic, debilitating and often deadly disease Diabetes is a chronic condition that arises when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin

More information

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health

More information

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)

More information

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body. International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

More information

Statistics of Type 2 Diabetes

Statistics of Type 2 Diabetes Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of: Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus

More information

Workshop A Tara Kadis

Workshop A Tara Kadis Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system

More information

Are insulin analogs worth their cost in type 2 diabetes?

Are insulin analogs worth their cost in type 2 diabetes? Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology

More information

Jill Malcolm, Karen Moir

Jill Malcolm, Karen Moir Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are

More information

Is Insulin Effecting Your Weight Loss and Your Health?

Is Insulin Effecting Your Weight Loss and Your Health? Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults

More information

Description. Comprehensive Education Courses Take Control Now! (2 Hour Session Billed to Insurance)

Description. Comprehensive Education Courses Take Control Now! (2 Hour Session Billed to Insurance) The University of Maryland Diabetes Network offers the latest available therapies, clinical trials and custom tailored care plans just for you. Education is a key component to living with and managing

More information

Faculty. Program Objectives. Introducing the Problem. Diabetes is a Silent Killer. Minorities at Greater Risk of Having Type 2 Diabetes

Faculty. Program Objectives. Introducing the Problem. Diabetes is a Silent Killer. Minorities at Greater Risk of Having Type 2 Diabetes Diabetes: The Basics Understanding and Managing Diabetes (Part 1 of 3) Satellite Conference Tuesday, October 18, 2005 2:00-4:00 p.m. (Central Time) Produced by the Alabama Department of Public Health Video

More information

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2

Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2 Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick

More information

Diabetes Medications: Insulin Therapy

Diabetes Medications: Insulin Therapy Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta

More information

Submission of Patient Evidence

Submission of Patient Evidence Ministry of Health and Long-Term Care Ontario Public Drug Programs 5700 Yonge Street, 3 rd Floor Toronto ON M2M 4K5 Submission of Patient Evidence Please send completed submission and/or any additional

More information

Updates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes

Updates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes dates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO Managing Complicated Diabetes Diabetes is increasingly common Managing diabetes and working as part of a multidisciplinary team is essential

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

DIABETES MELLITUS GUIDELINES

DIABETES MELLITUS GUIDELINES DIABETES MELLITUS GUIDELINES Virginia Premier Health Plan Virginia Premier Health Plan, Clinical Practice Guideline-Diabetes 1. Population screening a. Indications i. Adults of any age with body mass index

More information

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of

More information

MANAGEMENT OF TYPE - 1 DIABETES MELLITUS

MANAGEMENT OF TYPE - 1 DIABETES MELLITUS MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria

More information

Managing children and the young person with diabetes at school. A England September 2009

Managing children and the young person with diabetes at school. A England September 2009 Managing children and the young person with diabetes at school. A England September 2009 To establish the principles of managing Diabetes Mellitus Discuss the types of diabetes To inform/update staff of

More information

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.

More information

Type II diabetes: How to use the new oral medications

Type II diabetes: How to use the new oral medications Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.

More information

Type 2 diabetes Definition

Type 2 diabetes Definition Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes

More information

Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?

Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur? What is type 2 diabetes? Type 2 diabetes is a disorder that happens when your body does not make enough insulin or is unable to use its own insulin properly. The inability to use insulin is called insulin

More information

Insulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?

Insulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How? Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo

More information

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by

More information

Background (cont) World Health Organisation (WHO) and IDF predict that this number will increase to more than 1,3 million in the next 25 years.

Background (cont) World Health Organisation (WHO) and IDF predict that this number will increase to more than 1,3 million in the next 25 years. Diabetes Overview Background What is diabetes Non-modifiable risk factors Modifiable risk factors Common symptoms of diabetes Early diagnosis and management of diabetes Non-medical management of diabetes

More information

User guide Basal-bolus Insulin Dosing Chart: Adult

User guide Basal-bolus Insulin Dosing Chart: Adult Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For

More information

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!! Diabetic Ketoacidosis: When Sugar Isn t Sweet!!! W Ricks Hanna Jr MD Assistant Professor of Pediatrics University of Tennessee Health Science Center LeBonheur Children s Hospital Introduction Diabetes

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Type 2 diabetes in adults

Type 2 diabetes in adults Internal Clinical Guidelines Team Final draft : management Clinical Guideline Update (NG28) Methods, evidence and recommendations December 2015 Final draft Commissioned by the National Institute for Health

More information

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections. National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.

More information

Screening, Diagnosis and Management of Gestational Diabetes in New Zealand. A clinical practice guideline

Screening, Diagnosis and Management of Gestational Diabetes in New Zealand. A clinical practice guideline Screening, Diagnosis and Management of Gestational Diabetes in New Zealand 2014 Citation: Ministry of Health. 2014. Screening, Diagnosis and Management of Gestational Diabetes in New Zealand:. Wellington:

More information

Guidelines. for Sick Day Management for People with Diabetes

Guidelines. for Sick Day Management for People with Diabetes Guidelines for Sick Day Management for People with Diabetes When to Follow Sick Day Guidelines These guidelines apply when the person with diabetes is feeling unwell or noticing signs of an illness and/

More information